15 Essential Pharma Stories for Industry Leaders

Breaking news on pharmaceuticals from India's print media — this press review delivers media monitoring and media intelligence through print media monitoring, covering news on pharmaceuticals including drug safety, regulatory action, and patent disputes shaping the life sciences sector. According to Press Monitor's tracking of Indian publications, here are 15 essential stories for pharma and life sciences leaders.

1. USFDA Warning to Reliance Life Sciences

A front-page report in Mint says the USFDA has issued a warning letter to Reliance Life Sciences Pvt. Ltd over significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals at its manufacturing facility in Navi Mumbai. The USFDA issued a warning letter to Reliance Life Sciences Pvt. Ltd over significant CGMP violations at its Navi Mumbai manufacturing facility. This matters because USFDA actions can halt exports and trigger stock volatility across the pharma sector. Key detail: the violations involve finished pharmaceuticals at a major manufacturing site. Source: Mint. Next step: monitor Reliance Life Sciences' compliance response and potential impact on drug exports to the US.

2. Girl, 7, Dies After Chloroquine Dose in Andhra Village

A front-page report in The Hans India says a seven-year-old girl, Jamuna, died after falling unconscious following a chloroquine dose distributed during a malaria prevention drive in Gollaguppa village in Polavaram district. Thirty-two villagers have been discharged while 21 remain under treatment after falling sick, with only nine needing continued hospital care. Chief Minister N Chandrababu Naidu has ordered a full inquiry, and tablet samples have been sent to the Visakhapatnam Forensic Science Laboratory. A seven-year-old girl, Jamuna, died after falling unconscious following a chloroquine dose distributed during a malaria prevention drive in Gollaguppa village, Polavaram district. 70 people fell ill; 21 remain under treatment. Chief Minister N Chandrababu Naidu ordered a full inquiry and tablet samples were sent to the Visakhapatnam Forensic Science Laboratory. This highlights critical gaps in drug distribution at surveillance camps. Source: The Hans India. Next step: track state-level drug safety reforms and camp protocols.

3. Gujarat FDCA Cancels Licenses of 50 Pharma Firms

A front-page report in Free Press Journal says Gujarat's Food and Drug Regulatory Authority has cancelled the sales licences of 50 drug companies and seized 42,988 kg of suspected food items worth Rs 293.47 lakh in an August crackdown on fake medicines and adulteration. Health Minister Praful Pansheriya directed a zero tolerance approach, with inspections covering blood storage centres, restaurants and over 2,238 food businesses, while probes traced a fake drug supply chain from Lucknow to Ahmedabad and Sanand. Gujarat's Food and Drug Regulatory Authority cancelled sales licences of 50 drug companies and seized 42,988 kg of suspected food items worth Rs 293.47 lakh in an August crackdown on fake medicines and adulteration. Health Minister Praful Pansheriya directed a zero tolerance approach, with inspections covering blood storage centres, restaurants, and over 2,238 food businesses. Source: Free Press Journal. Next step: assess impact on Gujarat's pharma manufacturing ecosystem and supply chains.

4. West Bengal Chief Minister Destroys Illegal Cough Syrup

A front-page report in Free Press Journal says West Bengal Chief Minister Suvendu Adhikari on Wednesday had driven a road roller over 2 lakh seized cough syrup bottles which were illegal at North Bengal’s Balurghat. Bharatiya Janata Party (MP) and MoS Sukanta Majumdar was also present along with the Chief Minister when the ‘illegal’ cough syrup bottles were being crushed as a part of ‘Nasha Mukt Bharat’ drive. West Bengal Chief Minister Suvendu Adhikari drove a road roller over 2 lakh seized cough syrup bottles in Balurghat as part of the Nasha Mukt Bharat drive. BJP MP and MoS Sukanta Majumdar was also present. This demonstrates escalating government action against drug abuse and illegal pharmaceutical distribution. Source: Free Press Journal. Next step: watch for similar drives in other states and potential policy ripple effects.

5. Sun Pharma Semaglutide Samples for Novo Nordisk Patent Test

A front-page report in Free Press Journal says Pharma Laboratories Ltd. will provide samples of its semaglutide tablets to Novo Nordisk A/S for testing if it infringes on Pharma Labs’ patent. The high court is hearing an application by Sun Pharma Laboratories, a subsidiary of Sun Pharmaceutical Industries Ltd, to manufacture and market semaglutide tablets used to treat type 2 diabetes and manage chronic weight loss. Pharma Laboratories Ltd will provide semaglutide tablet samples to Novo Nordisk A/S for patent testing. The high court is hearing Sun Pharma Laboratories' application to manufacture and market semaglutide tablets used to treat type 2 diabetes and manage chronic weight loss. This patent dispute could reshape the GLP-1 market and generic drug access. Source: Free Press Journal. Next step: monitor court timelines and generic drug market implications.

6. Chemotherapy Cold Allodynia Brain Circuit Identified

A front-page report in Indian Express says researchers from the Indian Institute of Science and Kolkata-based TCG-CREST have identified the 'brain circuit' behind chemotherapy side effect 'cold allodynia'. Researchers from the Indian Institute of Science and Kolkata-based TCG-CREST identified the brain circuit behind chemotherapy side effect cold allodynia. This breakthrough could lead to targeted pain management for cancer patients undergoing treatment. Source: Indian Express. Next step: follow clinical trial developments and potential drug applications.

7. Munir Khan Trial Stalls After 14 Years

A front-page report in Free Press Journal says a special PMLA court in Mumbai has deferred framing of charges against self-proclaimed scientist and 'miracle doctor' Munir Khan, 14 years after he was accused, after his lawyers said he is mentally unfit to understand the proceedings due to deteriorating health. The Enforcement Directorate filed a prosecution complaint in March 2013 against Khan and three family members under the Prevention of Money Laundering Act. Khan allegedly cheated 120 people by claiming his medicine 'Body Revival', sold at Rs 15,000 for a 100-ml bottle, could cure all diseases, including cancer. A special PMLA court in Mumbai deferred framing of charges against self-proclaimed scientist and miracle doctor Munir Khan, 14 years after he was accused. The Enforcement Directorate filed a prosecution complaint in March 2013 against Khan and three family members under the Prevention of Money Laundering Act. Khan allegedly cheated 120 people by claiming his medicine Body Revival, sold at Rs 15,000 for a 100-ml bottle, could cure all diseases including cancer. Source: Free Press Journal. Next step: track PMLA court schedules and healthcare fraud policy developments.

8. India Plans to Curb Diversion of Legal Chemicals

A front-page report in Mint says India plans to curb the diversion of legal chemicals into illicit drugs by introducing a voluntary code of conduct for precursor chemicals. India plans to curb the diversion of legal chemicals into illicit drugs by introducing a voluntary code of conduct for precursor chemicals. This proactive regulatory approach addresses drug manufacturing supply chain vulnerabilities. Source: Mint. Next step: monitor industry feedback on the voluntary code and implementation timeline.

9. Novonesis Invests Rs 6,600 Crore in Maharashtra

A front-page report in Free Press Journal says Danish biosimilars producer Novonesis has announced a Rs 6,600 crore investment to expand its enzyme plant at Patalganga in Maharashtra over the next four years. The expanded facility, expected to be fully operational by 2030, will produce enzymes for industries including biofuels, household care, and food and beverages. Company president and chief executive Ester Baiget said the plant will help meet rising demand from emerging markets such as India, the Middle East, Africa and South Asia. Danish biosimilars producer Novonesis announced a Rs 6,600 crore investment to expand its enzyme plant at Patalganga in Maharashtra over the next four years, expected to be fully operational by 2030. Company president and CEO Ester Baiget said the plant will help meet rising demand from emerging markets such as India, the Middle East, Africa, and South Asia. Source: Free Press Journal. Next step: track investment impact on Maharashtra's biotech corridor and enzyme supply chains.

10. Elara Securities Recommends Buy for Alkem Laboratories

A front-page report in Business Line says that Elara Securities recommends a BUY rating for Alkem Laboratories with a target price of 76,533. The firm has established leadership in large acute therapies, supported by strong brands and a robust prescriber franchise. Elara Securities expects the company's focus on chronic and specialty therapies to improve domestic growth consistency and reduce seasonality. Elara Securities initiated a BUY rating for Alkem Laboratories with a target price of 76,533, citing leadership in large acute therapies, strong brands, and a robust prescriber franchise. Focus on chronic and specialty therapies is expected to improve domestic growth consistency and reduce seasonality. Source: Business Line. Next step: monitor Alkem's quarterly performance against analyst expectations.

11. Rise in Monsoon Illnesses and HINI Cases Boosts Vaccine Sales

A front-page report in Economic Times says that monsoon illnesses and a rise in HINI cases are boosting demand for acute therapies and vaccines, with sales of anti-infective and antibacterials rising l2% month-on-month in July. According to market research firm PharmaTrac, sales of anti-infectives rose to 22,359 crore in July 2O26 from 22,lO7 crore in June, while those of antibacterials increased to 22,lO9 crore from 2l,883 crore. Monsoon illnesses and rising HINI cases are driving demand for acute therapies and vaccines, with anti-infective sales rising 12% month-on-month in July to 22,359 crore. Antibacterial sales increased to 22,109 crore from 21,883 crore in June. Source: Economic Times. Next step: track seasonal pharma sales trends and inventory planning.

12. Bupicain Heavy Samples Fail Tests in Rajasthan

A front-page report in First India says seven Bupicain Heavy samples fail tests in Rajasthan, revealing bacterial endotoxins across multiple locations. Seven Bupicain Heavy samples failed tests across multiple locations in Rajasthan, revealing bacterial endotoxin contamination. This raises serious drug quality concerns and potential recall implications. Source: First India. Next step: monitor FDA and CDSCO response and manufacturer actions.

13. Aarogyasri Suppliers Halt Drugs Over Dues

A front-page report in Deccan Chronicle says suppliers to government hospitals in Hyderabad have stopped supplying critical medical equipment, surgical items and drugs under the Rajiv Aarogyasri scheme. They said payments have been pending for nearly two years. Suppliers to government hospitals in Hyderabad stopped supplying critical medical equipment, surgical items, and drugs under the Rajiv Aarogyasri scheme, citing nearly two years of pending payments. This threatens healthcare delivery in Telangana. Source: Deccan Chronicle. Next step: track government resolution of payment delays and impact on patient care.

14. Allahabad HC on Codeine Misuse

A front-page report in Free Press Journal says the Allahabad High Court has ruled that codeine-based cough syrup diverted for intoxication can attract provisions of the NDPS Act, even when the medicine contains codeine within permissible limits. The court clarified that codeine preparations are exempt from the NDPS law only when used for legitimate medical purposes, while diversion, storage, transport or sale for intoxication or illegal trafficking can be treated as manufactured drugs. However, licensed retailers selling permitted formulations for genuine medical use may face action under the Drugs and Cosmetics Act for regulatory violations rather than automatic NDPS offences. The Allahabad High Court ruled that codeine-based cough syrup diverted for intoxication can attract NDPS Act provisions, even when the medicine contains codeine within permissible limits. Licensed retailers selling permitted formulations for genuine medical use may face action under the Drugs and Cosmetics Act for regulatory violations. Source: Free Press Journal. Next step: monitor implications for pharmaceutical retail licensing and codeine regulation.

15. How to Find Your Nearest Jan Aushadhi Store

A front-page report in Times of India says that patients may not know where to find government-supported Jan Aushadhi stores selling generic medicines. To find nearby stores, use the official Jan Aushadhi locator. Patients may not know where to find government-supported Jan Aushadhi stores selling generic medicines. The official Jan Aushadhi locator tool is available to help find nearby stores. Source: Times of India. Next step: promote awareness of affordable generic medicine access and the locator tool.

This press review demonstrates the power of print media monitoring for staying ahead in pharmaceuticals and life sciences. Which story surprised you most? Share your thoughts in the comments.